U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07083323) titled 'A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors' on July 06.
Brief Summary: This is a multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary clinical efficacy of HY05350 for injection in patients with MSLN-positive advanced solid tumors.
Study Start Date: July 31
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor
Intervention:
DRUG: HY05350 for injection
HY05350 should be administered intravenously at planned dosage, once a week, once every two weeks, or once every three weeks, until disease progression or...